NIH Reporter #1RF1AG094856-01

Research Project: Biomaterials to Inhibit Amyloid Beta Aggregation for Alzheimer's Disease

This opportunity involves a research procurement by the University of South Florida focused on Alzheimer's disease treatment innovations. - Government Buyer: - University of South Florida - Project Scope: - Research project to develop biomaterials that inhibit Abeta42 aggregation, a key factor in Alzheimer's disease - Design and synthesis of helix-stabilizing peptidomimetic biomaterials (helical peptidic foldamers) - Includes both in vitro and in vivo testing to assess efficacy in preventing and disrupting amyloid beta (Aβ) aggregation - Products/Services Requested: - One comprehensive research project (lump sum) - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Notable Requirements: - Emphasis on innovative biomaterials targeting amyloid beta structures - Focus on both prevention and disruption of Aβ aggregation, directly addressing amyloid toxicity in Alzheimer's disease - Estimated contract value: $3,297,926

Description

This project aims to develop biomaterials targeting amyloid beta structures to treat Alzheimer's disease. The work involves designing helical peptidic foldamers and conducting both in vitro and in vivo testing. The goal is to prevent and disrupt Aβ aggregation, which is implicated in amyloid toxicity. The procurement is for a research project on amyloid toxicity.

View original listing